Journal of Laboratory Medicine and Quality Assurance

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2288-7261   pISSN 2384-2458

Table. 17.

Table. 17.

2017 external quality assessment result of rapid antituberculous drug resistance test (RIF)

MTB DNA, drug (RIF) resistance mutation1st trial2nd trial3rd trial



GT1703GT1704GT1708GT1709GT1713GT1714






R (%)S (%)R (%)S (%)R (%)S (%)R (%)S (%)R (%)S (%)R (%)S (%)
Cepheid27 (100)27 (100)28 (100)28 (100)35 (100)35 (100)
 Xpert MTB/RIF27 (100)27 (100)28 (100)28 (100)35 (100)35 (100)
Hain Lifescience13 (100)13 (100)13 (100)13 (100)12 (100)12 (100)
 GenoType MTBDRplus13 (100)13 (100)13 (100)13 (100)12 (100)12 (100)
LG Chem6 (100)6 (100)6 (100)6 (100)7 (100)7 (100)
 AdvanSure TB/NTM real-time PCR6 (100)6 (100)6 (100)6 (100)7 (100)7 (100)
Others4 (100)4 (100)4 (100)4 (100)4 (100)4 (100)
Seegene3 (100)3 (100)3 (100)3 (100)4 (100)4 (100)
 Seegene anyplex MDR-TB detection3 (100)3 (100)3 (100)3 (100)4 (100)4 (100)
YD Diagnostics1 (100)1 (100)1 (100)1 (100)
 MolecuTech REBA MTB-MDR1 (100)1 (100)1 (100)1 (100)
All53 (100)53 (100)55 (100)55 (100)63 (100)63 (100)

The instrument used was from the following company: Cepheid (Sunnyvale, CA, USA); Hain Lifescience (Nehren, Germany); LG Chemical (Seoul, Korea); Seegene (Seoul, Korea); and YD Diagnostics (Yongin, Korea).

Abbreviations: MTB, Mycobacterium tuberculosis; R, resistant; S, susceptible; RIF, rifampicin; NTM, nontuberculous mycobacteria; PCR, polymerase chain reaction.

J Lab Med Qual Assur 2019;41:82-104 https://doi.org/10.15263/jlmqa.2019.41.2.82
© 2019 J Lab Med Qual Assur